Viatris

Summary

More than a million people now live with Multiple Sclerosis (MS) in Europe. The personal and societal burden of MS multiplies with increasing disability. The goal is therefore to control inflammatory activity, prevent relapses and slow cumulative disability.

In this webinar, we will highlight the burden of MS, discuss its earlier diagnosis, and review the evidence for early treatment leading to better responses and a more favorable course of illness. We also examine the use of biomarkers to monitor prognosis and to anticipate treatment response and take a closer look at those with MS who may require special attention.

Agenda

SESSION 1:

Introduction

17:00 – 17:10

Prof. Celia Oreja-Guevara

SESSION 2:

The importance of an early diagnosis and the use of biomarkers to anticipate treatment response

17:10 - 17:30

Prof. Hans-Peter Hartung

SESSION 3:

Special populations in MS

17:30 - 17:50

Dr. Karen Chung

SESSION 4:

Q&A

17:50 - 18:00

18:00

Know the Speakers

Prof. Celia Oreja-Guevara
MS Neurologist

Head of MS Center University Hospital San Carlos Madrid, Spain.

Prof. Hans-Peter Hartung
MS Neurologist

Chairman of the Department of Neurology Heinrich-Heine University Düsseldorf, Germany.

Dr. Karen Chung
MS Neurologist

Consultant Neurologist University College London Hospitals London, United Kingdom.

Registration form

First Name *

Last Name *

Email *

Country *

Specialty *

Organization Name *

Organization - Street/Building No

Organization - Zip or Postal Code

Professional Registration Number

Applicable national laws and codes of practice prohibit the advertising of prescription-only medicines to the general public (e.g. patients or patient organizations) and other nonprescribers. The marketing authorization holder must be able to recognize these groups to avoid approaching them with advertising. By ticking this checkbox, you confirm that you are licensed/authorized to prescribe medicines or otherwise entitled to receive advertising in line with local laws applicable to you, e.g. as a pharmacist. * I confirm, I have read the Viatris Privacy Notice at www.viatris.com/en/privacy-policy and agree that Viatris Inc., its affiliates and subsidiaries (“Viatris”) may use my personal data to provide me with scientific information and information on pharmaceutical products as well as events, webinars or surveys. I understand and acknowledge that all information processed by Viatris is handled in accordance with local privacy laws and may be captured and processed in countries outside of the jurisdiction in which it was collected. In order to improve its emails, websites and information services, Viatris may track whether I received an email, opened it, clicked on any links, viewed or downloaded any documents within it. I understand that my consent is voluntary and I can withdraw my consent at any time. The withdrawal of consent will not affect the lawfulness of processing based on consent before its withdrawal. I acknowledge that I am not obliged to provide my personal information. However, if I do not provide the information, I may not, for example, be able to participate fully in activities managed by Viatris.